Table 3.
List of phytochemicals currently in clinical trial on various cancers.
| Phytochemical | Class of compound | Type of cancer | Assessment | Reference |
|---|---|---|---|---|
| Berberine (alkaloid) | Berberis sp. (Berberidaceae) | Colorectal cancer | Prevention of recurrence | NCT03281096* |
| Curcumin (polylphenol) | Curcuma longa (Zingiberaceae) | Advanced and metastatic breast cancer | Quality of life, safety in combination, progression free survival, time to disease Progression, and time to treatment failure | NCT03072992* |
| Epigallocatechin (flavonoids) | Camellia sinensis (Theaceae) | Colorectal cancer | Change in methylation pattern compare to baseline | NCT02891538* |
| Lycopene (carotenoids) | Solanum lycopersicum (Solanaceae) | Metastatic colorectal cancer | Effectiveness in reducing skin toxicity alone or in combination with panitumumab. Pharmacokinetics. | NCT03167268* |
| Quercetin (carotenoids) | Prostate cancer | EGCG, ECG, quercetin, and their methylated metabolites in prostate tissue and plasma. Enzyme activity expression of COMT, DNMT1, and MRP1. Inter-individual variation in genotype of COMT | NCT01912820* | |
| Resveratrol (stilbenoid) | Polygonum cuspidatum (Polygonaceae) | Low-grade GI neuroendocrine tumors | Notch1 activation, toxicity | NCT01476592* |
| Sulforaphane (isothiocyanate) | Brassica oleracea (Brassicaceae) | Former smokers with a high risk of developing lung cancer | Bronchial dysplasia index, cell proliferation marker Ki-67, apoptosis markers including caspase-3 and TUNEL | NCT03232138* |
*Indicates reference found at www.clinicaltrials.gov with corresponding identifier code (NCT).